Medicare does not cover weight-loss drugs. That has been the law since the program began. A prescription could run a thousand dollars a month, and if the label said weight loss, Part D would not pay.
On July 1, that changed. The government launched a temporary program called the Medicare GLP-1 Bridge. For the first time in the program’s history, it started covering the prescription. The copay: $50 a month.
The program is called the Medicare GLP-1 Bridge. GLP-1 drugs are a class of medications that include Wegovy, Zepbound, and a newer one called Foundayo. They reduce appetite and produce significant weight loss. More than 16 million Americans have used them. They cost $700 to $1,000 a month at full price.
3.8M
Medicare beneficiaries estimated eligible for the Bridge program (KFF)
$1,000
Monthly out-of-pocket cost before the program launched
$50
Monthly copay under the Bridge. The price the cohort actually pays now.
KFF estimates 3.8 million Medicare beneficiaries qualify for the Bridge. CMS expects “several million” to enroll. Novo Nordisk and Eli Lilly make these drugs. They estimate 15 to 20 million older adults in Medicare could eventually qualify for coverage.
To qualify you need a Part D plan and a BMI of 35 or higher. A BMI of 27 also works if you have a qualifying condition like prediabetes or heart disease. Prior authorization is required. The program operates outside of Part D entirely. That means the $50 copay does not count toward your deductible or your annual out-of-pocket cap.
This is a longevity purchase. It sits in the aisle after the doctor, after the room, after the second knee. Spending on more good years, at a price the cohort can finally reach.
Where the $50 prescription lands on the schedule.
The catch is the clock. The Bridge program expires December 31, 2027. After that, Congress would have to change federal law to make the coverage permanent, and no bill has passed yet. The $50 price comes with a timer, and the companies building supply chains around it know the timer is running.
For seniors who qualify, $50 a month is real money in a real pocket. But it is also $600 a year on a drug that did not exist in the budget before. Multiply that across millions of new prescriptions and you see the longevity aisle opening in front of you. Spending on more good years, arriving on a government schedule, at a price this generation can finally afford to pay.
The arithmetic
The $50 monthly copay and program dates (July 1, 2026 through December 31, 2027) from CMS, Medicare GLP-1 Bridge announcement, May 2026. Eligible beneficiaries (3.8 million) from the Kaiser Family Foundation analysis of 2023 Part D enrollment data, published June 2026. The 15-to-20-million broader eligibility estimate from Novo Nordisk and Eli Lilly via CNBC, June 30, 2026. Pre-Bridge out-of-pocket cost ($700 to $1,000/month) from JAMA Network Open, fiscal impact study, May 2026. Total GLP-1 users (more than 16 million) from CNBC. Program cost estimates ($1.3 billion to $3.3 billion at 10 to 25 percent participation) from KFF. Analyst revenue projection (more than a billion annually per company) from Leerink Partners via CNBC. Eligibility criteria (BMI, qualifying conditions, prior authorization) from CMS provider guidance, July 2026.
My friend picked up his prescription last Tuesday. Fifty dollars. He told me it felt like someone had made a clerical error. It was not an error. It was the longevity aisle opening its doors. Watch who fills the shelves.
Andrew
Boomers Trade is written by someone getting older right alongside you, and watching who profits from it.
|